Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFNβ

Background: Neutralizing anti-drug antibodies (ADA) can greatly reduce the efficacy of biopharmaceuticals used to treat patients with multiple sclerosis (MS). However, the biological factors pre-disposing an individual to develop ADA are poorly characterized. Thus, there is an unmet clinical need fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Waddington, Kirsty E., Papadaki, Artemis, Coelewij, Leda, Adriani, Marsilio, Nytrova, Petra, Kubala Havrdova, Eva, Fogdell-Hahn, Anna, Farrell, Rachel, Dönnes, Pierre, Pineda-Torra, Inés, Jury, Elizabeth C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380268/
https://www.ncbi.nlm.nih.gov/pubmed/32765529
http://dx.doi.org/10.3389/fimmu.2020.01527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380268/
https://www.ncbi.nlm.nih.gov/pubmed/32765529
http://dx.doi.org/10.3389/fimmu.2020.01527

Ejemplares similares